Nadobna G
Wrocław Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nadobna G.
Clinical Drug Investigation | 2002
Zak-Nejmark T; Małolepszy J; Maria Kraus-Filarska; Tadeusz Dobosz; Marek Jutel; Nadobna G; Anna Jonkisz
AbstractBackground: Histamine H1 and H2 receptors both belong to a family of G protein-coupled receptors that often show opposite actions on cell activity. Ebastine, a piperidine derivative, and its active metabolite, carebastine, are very potent second-generation histamine H1 receptor antagonists. Objective: To investigate the influence of treatment with ebastine on the expression of histamine H1 receptor and H2 receptor mRNA on peripheral blood mononuclear cells (PBMC). Patients: The study was performed in five grass pollen-allergic individuals with seasonal allergic rhinitis. All subjects showed positive skin-prick tests with mixed grass pollen. The study was performed out of the grass pollen season. Methods: Blood samples were obtained before and after treatment with ebastine (Kestine®, Rhône-Poulenc-Rorer, France) 10 mg/day for 7 days. PBMC were isolated using density-gradient centrifugation. Histamine H1 and H2 receptor mRNA expression were determined using semiquantitative reverse transcription polymerase chain reaction. Results: Prior to ebastine treatment, mRNA expression measured by the peak area for histamine H1 and H2 receptors was 33, 323 (± 33, 269) relative fluorescence units (RFU)and 59, 511 (± 31, 621) RFU, respectively. After treatment, histamine H1 and H2 receptor mRNA expression increased to 42, 061 (± 28, 263 ) and 89, 913 (+ 13, 053) RFU, respectively, and this difference was statistically significant (p < 0.01) in contrast to the difference prior to the treatment. Ebastine-induced histamine H1 and H2 receptor upregulation, however, moved the balance towards histamine H2 receptor dominance. Conclusions: In conclusion, ebastine induced H1 and H2 receptor upregulation, but moved the balance towards H2 receptor dominance. This potent H1 receptor antagonist, in addition to reducing allergic symptoms, is able to influence inflammatory responses. Since H2 receptor stimulation shows suppressive effects on cell activation, this can contribute to long-term anti-inflammatory actions of anti-histamines.
Archivum Immunologiae Et Therapiae Experimentalis | 1991
Zak-Nejmark T; Małolepszy J; Osos M; Nadobna G; Marek Jutel
Archivum Immunologiae Et Therapiae Experimentalis | 2000
Zak-Nejmark T; Maria Kraus-Filarska; Małolepszy J; Jankowska R; Marek Jutel; Iwona Anna Nowak; Nadobna G
Archivum Immunologiae Et Therapiae Experimentalis | 1992
Zak-Nejmark T; Małolepszy J; Marek Jutel; Nittner-Marszalska M; Nadobna G
Archivum Immunologiae Et Therapiae Experimentalis | 1996
Zak-Nejmark T; Jankowska R; Małolepszy J; Marek Jutel; Maria Kraus-Filarska; Nadobna G
Archivum Immunologiae Et Therapiae Experimentalis | 1992
Zak-Nejmark T; Małolepszy J; Nadobna G; Krystyna Kuczynska-Sekieta; Ewa Marczynska-Sarul; Marek Jutel
Central European Journal of Immunology | 2004
Teresa Żak-Nejmark; Maria Kraus-Filarska; Krzysztof Wytrychowski; Małolepszy J; Anna Jonkisz; Nadobna G
Central European Journal of Immunology | 2004
Teresa Żak-Nejmark; Maria Kraus-Filarska; Małolepszy J; Monika Cembrzyńska-Nowak; Nadobna G; Małgorzata Bieńkowska-Haba
Archivum Immunologiae Et Therapiae Experimentalis | 1994
Jankowska R; Zak-Nejmark T; Małolepszy J; Nadobna G; Osos M; Medrala W
Archivum Immunologiae Et Therapiae Experimentalis | 1993
Zak-Nejmark T; Małolepszy J; Marek Jutel; Wrzyszcz M; Nadobna G